Human isotope fractional absorption studies comparing chelated Magnesium Glycinate vs. Citrate vs. 4% Oxide, CYP2R1/CYP27B1 magnesium-dependent Vitamin D3 activation trials, and Metformin-induced Vitamin B12 holotranscobalamin depletion. Explore 4,327 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Preliminary findings suggest that the mental health benefits of chronic RET were independent of placebo effects, notwithstanding the potential limitations of small sample size and the non-mode-specific measure of expectations.
This study provides support for acne treatment with CAB in ethnically diverse populations.
The test freeze-dried live attenuated VarV demonstrated good immunogenicity and higher safety compared to the active control vaccine in healthy participants aged 13-55 years.
As a result of the coronavirus disease 2019 pandemic, asthma exacerbation rates were much lower than expected, contributing to the primary endpoint not being met.
These analyses suggest that elevated post-nephrectomy plasma KIM-1 level and kinetics are prognostic, supporting the hypothesis that KIM-1 is a biomarker for minimal residual disease in RCC.
Tafamidis treatment reduced the risk of mortality and hospitalization in patients with NAC stages I/II ATTR-CM, with favourable trends at stage III.
Conclusions: These findings suggest that self-compassion may play a critical role in the therapeutic effects of MDMA-AT.
Results from the population PK model and E-R analyses reinforce the evidence base for valbenazine efficacy in reducing chorea severity, as demonstrated by the notable decrease in TMC scores compared to baseline.
Amlitelimab treatment led to clinically meaningful improvements in COAs by Week 24 versus placebo.
The freeze-dried live attenuated VarV developed by Beijing Minhai Biotechnology Co.
Applied to the skin GT20029 demonstrated significant efficacy in hair regrowth with good tolerability.
Kidney function did not impact staying on track with medication, quantifiable CMV DNAemia, or prophylaxis discontinuation in the letermovir group; however, staying on track with medication was lower, and quantifiable CMV...
This study utilizes data from a large clinical trial to establish a method with high specificity for exploring clonal engraftment from microbiota-based treatments to facilitate future how the body absorbs the medicine and how...
Carotegrast methyl appears most effective in patients with moderately active ulcerative colitis with low disease activity, with week 2 and beyond as an appropriate time point for assessing efficacy.
Weight loss resulting from lifestyle interventions is associated with reductions in plasma BCAA concentrations.
In a pooled analysis, slow heart rate was observed in 6% of terlipressin-treated patients but rarely required a dose interruption or reduction.
The onset of action for fezolinetant was observed from day 1 for VMS frequency and severity and was maintained for 52 weeks.
Guselkumab, a fully human monoclonal antibody able to bind CD64 and simultaneously inhibit the IL-23p19 subunit, provided significantly higher rates of clinical improvement and significant inhibition of structural damage...
LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer.
Both the $PRIOR and pooled population how the body absorbs the medicine methods yielded more accurate results compared to conventional NCA.
Venlafaxine ER has a favorable benefit-risk profile in adult Japanese patients with GAD, indicating its potential to improve GAD symptoms as well as patients' function and exert superior anxiolytic effects over placebo without...
We present and propose the use of a pharmacometric-based body composition model to describe weight reduction in future clinical trials investigating similar drugs in similar patient populations, in lieu of DXA scans.
COPDPredict™ failed to show a reduction in severe AECOPD events resulting in hospitalisations, although the number of admissions per participant was lower among users.
A low-dose prednisone plus methotrexate regimen is non-inferior to standard-dose prednisone in achieving full symptom relief in idiopathic retroperitoneal fibrosis, allowing significant reduction in glucocorticoid exposure.
This study supports the use of MenACYW-TT in infants aged 6 weeks (42 days) or older.
Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
Moreover, the magnitude of the immune response was similar to the antibody levels detected in sera from convalescent chikungunya patients.
In patients with COMISA, the combination of eszopiclone with BBTI resulted in comparable improvement in sleep quality of life to that achieved with BBTI-only therapy.
Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy.
Responders additionally reported greater improvement from baseline than non-responders for measures of AA-related emotional symptoms, mental health, and work or activity limitations.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
